A new analysis suggests acoramidis may improve kidney health over time in people with transthyretin amyloid cardiomyopathy (ATTR-CM). BridgeBio Pharma, the company that markets the drug, announced the findings, which appear in Circulation: Heart Failure.
The U.S. Food and Drug Administration (FDA) approved acoramidis (marketed as Attruby) for adults with wild-type or hereditary ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. It is not approved specifically as a kidney-protective treatment, but the study explored whether kidney-related effects may be part of its broader clinical profile.
People with ATTR-CM are at risk for heart failure, and heart and kidney function are closely related. For that reason, kidney health is often an important part of care for people being treated for heart disease. “Kidney dysfunction is pervasive in this population and an independent predictor of mortality from ATTR-CM,” said Dr. Jeffrey Testani, first author of the manuscript.